Randomized Trialhigh evidence
In intermediate-risk PE, adding US-CDT to anticoagulation reduced a composite adverse clinical outcome within 7 d.
Annals of internal medicine·July 1, 2026·PMID 42407064
Why it mattersIntermediate-risk PE carries a substantial risk of early decompensation despite anticoagulation. This trial clarifies that US-CDT can improve short-term outcomes, offering a targeted intervention for emergency physicians and cardiologists managing these patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled